2018 American Transplant Congress
Metabolic Therapy as a Platform for CTLA4Ig Costimulation Blockade in Preventing Allograft Rejection
The backbone of current immunosuppression regimens remains calcineurin inhibitors (CNI) in association with steroids, mycophenolate mofetil or mTOR inhibitors. However, their long-term administration is associated…2018 American Transplant Congress
Clinical Impact of Denovo or Recurrent Donor Specific Antibodies in the First Year Post Kidney Transplant in Patients on Early Steroid Withdrawal Immunosupression Regimen
Division of Renal Disease and Hypertension, Indiana University Health, Indianapolis, IN.
Background: Immunologic risk monitoring of recipients of kidney transplant(Tx) using donor specific antibodies (DSA) has become a standard practice in most Tx centers in the…2018 American Transplant Congress
Association of CYP3A5*3*6*7 Metabolic Composites to Tacrolimus Pharmacokinetics in African American and Caucasian Renal Transplant Recipients
Background: Interpatient variability in tacrolimus pharmacokinetics(PK) is due primarily to metabolism by cytochrome P-450 3A5(CYP3A5) isoenzymes. African Americans(AA) require higher tacrolimus doses to achieve comparable…2018 American Transplant Congress
Hyperkalemia in the Early Post Renal Transplant Period
Hyperkalemia is a recognized and potentially life threatening complication post renal transplantation. Aside from delayed graft function, the most frequent culprit identified is pharmacotherapy. Many…2018 American Transplant Congress
Association between Everolimus Trough Levels, Onset of Related Adverse Events, and Treatment Discontinuation after Liver Transplantation: 24-Month Results from the H2304 Study
Purpose: Evaluation of mammalian target of rapamycin inhibitor (mTORi)-related adverse events (AEs) and drug trough levels (C0) at onset may aid their management in liver…2018 American Transplant Congress
Greater Susceptibility for Metabolic Syndrome in Pediatric Transplant Recipients – A Case-Control Study
Introduction. Metabolic syndrome not only contributes to an increased risk for cardiovascular sequelae but is also associated with impaired graft function and lower graft survival…2018 American Transplant Congress
Simplified Once-Daily Immunosuppressive Regimen for Stable Kidney Recipients
Background. Many immunosuppressive drugs are prescribed as twice-daily dosing. Simplified once-daily dosing of the entire drug regimen can improve treatment satisfaction for patients. We examined…2018 American Transplant Congress
Presence of Chronic Vascular Lesions on Allograft Biopsy is Associated with Greater Improvement in Renal Function after Conversion from Tacrolimus to Belatacept
Background: Conversion from tacrolimus to belatacept has been shown to be beneficial for an increasing number of kidney transplant (KT) patients. However, predicting factors for…2018 American Transplant Congress
Pharmacokinetics of Mycophenolic Acid Following Enteric-Coated Mycophenolate Sodium Administration in Chinese Renal Transplant Recipients
MyERA Study Group, Hangzhou, China.
Background: Mycophenolic acid (MPA), active component of mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium (EC-MPS), is the most commonly used immunosuppressant in renal transplant recipients…2018 American Transplant Congress
Once-Daily Prolonged-Release Tacrolimus versus Twice-Daily Tacrolimus in Liver Transplantation: A Meta-Analysis
Background: A prolonged-release formulation of tacrolimus has been developed to provide once-daily dosing, with similar efficacy and safety to the standard twice-daily dosing and it…
- « Previous Page
- 1
- …
- 80
- 81
- 82
- 83
- 84
- …
- 138
- Next Page »